BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it has won first prize in Deloitte's Technology Fast 50 2009TM ranking of France's fastest-growth technology companies.
The ranking is drawn up according to turnover growth over the fiscal years 2004 to 2008. During this period, BioAlliance Pharma's earnings grew 70-fold to reach €8.2 million.
This strong growth is due to the success of Loramyc® (indicated for the treatment of oral candidiasis in immunocompromised patients), the first product to be developed by BioAlliance Pharma and launched on the French market. Loramyc® has already received marketing authorizations in 12 European countries and is going through the registration process in the United States. BioAlliance Pharma has already signed Loramyc® industrial partnerships in the United States and South-East Asia.
"Today, BioAlliance Pharma is in a unique position to leverage its assets and innovation skills and keep on growing. Our assets are based around Setofilm® (a second supportive care product that we expect to market in 2010) and positive Phase III clinical trial results for another product administered through mucosal route (in the treatment of oro-facial herpes)," commented Dominique Costantini, President and CEO of BioAlliance Pharma. "We are delighted to have topped the Deloitte ranking, which acknowledges our ability to go from bench to market and transform innovations into medically proven products with added value for patients."
"Inclusion in the Deloitte Technology Fast 50TM means being one of France's leaders in terms of five-year growth and demonstrates exceptional qualities in today's highly competitive technology markets," added Eric Morgain, partner in charge of the Technology Fast 50TM program at Deloitte. "We heartily congratulate BioAlliance Pharma on being one of France's fastest-growing technology companies."